Sign Out
Asthma: Fasenra is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists (see Pharmacology: Pharmacodynamics under Actions).
Eosinophilic granulomatosis with polyangiitis (EGPA): Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (see Pharmacology: Pharmacodynamics under Actions).
Continue with Google